For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...